DSpace Repository

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Show simple item record

dc.creator Paksoy, Nail
dc.creator KAHRAMAN, SEDA
dc.creator Erul, Enes
dc.creator Seyyar, Mustafa
dc.creator GÜMÜŞAY, ÖZGE
dc.creator Bayram, Ertugrul
dc.creator Demirel, Burcin Cakan
dc.creator Acar, Omer
dc.creator AKSOY, SERCAN
dc.creator Baytemur, Naziyet Kose
dc.creator ŞAHİN, ELİF
dc.creator ÇABUK, DEVRİM
dc.creator BAŞARAN, Gül
dc.creator PAYDAŞ, SEMRA
dc.creator YAREN, ARZU
dc.creator Guven, Deniz Can
dc.creator Erdogan, Atike Pinar
dc.creator Demirci, Umut
dc.creator Yasar, Alper
dc.creator BAYOĞLU, İBRAHİM VEDAT
dc.creator HIZAL, MUTLU
dc.creator Gulbagci, Burcu
dc.creator Davarci, Sena Ece
dc.creator Yilmaz, Funda
dc.creator Dogan, Ozlem
dc.creator Orhan, Sibel Oyucu
dc.creator Aytac, Ali
dc.creator KESKİNKILIÇ, MERVE
dc.creator EYLEMER MOCAN, EDA
dc.creator Unal, Olcun Umit
dc.creator Aydin, Esra
dc.creator Yucel, Hakan
dc.creator Isik, Deniz
dc.creator Eren, Onder
dc.creator OYAN ULUÇ, BAŞAK
dc.creator Ozcelik, Melike
dc.creator HACIBEKİROĞLU, İLHAN
dc.creator Aydiner, Adnan
dc.creator Demir, Hacer
dc.creator Oksuzoglu, Berna
dc.creator Cilbir, Ebru
dc.creator ÇUBUKÇU, ERDEM
dc.creator Oktay, Esin
dc.creator EROL, CİHAN
dc.creator Okutur, Sadi Kerem
dc.creator Yildirim, Nilgun
dc.creator Alkan, Ali
dc.creator Selcukbiricik, Fatih
dc.creator Aksoy, Asude
dc.creator Karakas, Yusuf
dc.creator Ozkanli, Gulhan
dc.creator Duman, Berna Bozkurt
dc.creator Aydin, Dincer
dc.creator Dulgar, Ozgecan
dc.creator Er, Muhammed Muhiddin
dc.creator Teker, Fatih
dc.creator YAVUZŞEN, TUĞBA
dc.creator Aykan, Musa Baris
dc.creator Inal, Ali
dc.creator Iriagac, Yakup
dc.creator Kalkan, Nurhan Onal
dc.creator Keser, Murat
dc.creator Sakalar, Teoman
dc.creator Menekse, Serkan
dc.creator Kut, Engin
dc.creator Bilgin, Burak
dc.creator Karaoglanoglu, Muge
dc.creator Sunar, Veli
dc.creator Ozdemir, Ozlem
dc.creator Turhal, Nazim Serdar
dc.creator Karadurmus, Nuri
dc.creator YALÇIN, BÜLENT
dc.creator ŞENDUR, MEHMET ALİ NAHİT
dc.creator KAYIKÇIOĞLU, Erkan
dc.creator ÇETİN, Bülent
dc.date 2023-03-01T00:00:00Z
dc.date.accessioned 2025-02-25T10:23:46Z
dc.date.available 2025-02-25T10:23:46Z
dc.identifier 6b4454d1-de76-4c63-9dab-2c0deccc7b07
dc.identifier 10.2217/fon-2022-1287
dc.identifier https://avesis.sdu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/100048
dc.description Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
dc.language eng
dc.rights info:eu-repo/semantics/closedAccess
dc.title Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.type info:eu-repo/semantics/article


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account